A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed on or After Platinum-based Chemotherapy
Latest Information Update: 16 Oct 2024
At a glance
- Drugs Avelumab (Primary)
- Indications Penile cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms ALPACA
- 10 Oct 2024 Planned primary completion date changed from 30 Jun 2024 to 31 Dec 2024.
- 01 Feb 2024 Planned End Date changed from 30 Jun 2023 to 31 Dec 2024.
- 01 Feb 2024 Planned primary completion date changed from 30 Jun 2023 to 30 Jun 2024.